m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04276)
Name
FP-1201
Synonyms
Traumagen; Traumakine; MR-11-A-8; CD73 agonist (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/MaruishiPharmaceutical; Interferon beta-1a (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/Maruishi Pharmaceutical
    Click to Show/Hide
Status
Phase 3
TTD Drug ID
D05LOB
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Interferon-beta (IFNB1)
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for FP-1201. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of FP-1201 through regulating the expression of Interferon-beta (IFNB1). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for FP-1201. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of FP-1201 through regulating the expression of Interferon-beta (IFNB1). [2], [3]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for FP-1201. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of FP-1201 through regulating the expression of Interferon-beta (IFNB1). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for FP-1201. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of FP-1201 through regulating the expression of Interferon-beta (IFNB1). [2], [4]
References
Ref 1 Influence of N6-Methyladenosine Modification Gene HNRNPC on Cell Phenotype in Parkinson's Disease. Parkinsons Dis. 2021 Dec 20;2021:9919129. doi: 10.1155/2021/9919129. eCollection 2021.
Ref 2 Pegylated interferon Beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.
Ref 3 RNA m(6) A modification enzymes shape innate responses to DNA by regulating interferon Beta. Genes Dev. 2018 Dec 1;32(23-24):1472-1484. doi: 10.1101/gad.319475.118. Epub 2018 Nov 21.
Ref 4 m(6)A modification controls the innate immune response to infection by targeting type I interferons. Nat Immunol. 2019 Feb;20(2):173-182. doi: 10.1038/s41590-018-0275-z. Epub 2018 Dec 17.